济民健康
(603222)
| 流通市值：52.46亿 | | | 总市值：52.46亿 |
| 流通股本：5.25亿 | | | 总股本：5.25亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 163,097,985.21 | 685,962,950.12 | 544,718,299.64 | 366,449,449 |
| 营业收入 | 163,097,985.21 | 685,962,950.12 | 544,718,299.64 | 366,449,449 |
| 二、营业总成本 | 185,180,092.87 | 808,988,867.45 | 592,923,784.23 | 397,731,310.44 |
| 营业成本 | 108,204,176.92 | 472,971,795.98 | 348,045,819.3 | 231,349,638.74 |
| 税金及附加 | 2,769,606.42 | 12,968,894.93 | 9,574,899.43 | 6,737,022.5 |
| 销售费用 | 31,807,526.29 | 139,516,783.49 | 104,068,515.79 | 72,014,066.32 |
| 管理费用 | 27,707,853.9 | 111,527,422.8 | 84,572,171.24 | 57,297,306.04 |
| 研发费用 | 8,423,573.52 | 47,921,341.84 | 30,535,831.43 | 19,872,078.24 |
| 财务费用 | 6,267,355.82 | 24,082,628.41 | 16,126,547.04 | 10,461,198.6 |
| 其中:利息费用 | 6,014,337.35 | 23,987,806.37 | 17,930,270.81 | 11,733,242.8 |
| 其中:利息收入 | 239,822.37 | 2,517,553.91 | 2,177,819.32 | 1,440,886.11 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -1,722.84 | -8,062.73 | -7,309.28 | -6,743.31 |
| 资产处置收益 | - | -68,690.52 | -68,690.52 | -68,690.52 |
| 资产减值损失(新) | -1,306,941.97 | -78,214,265.32 | -35,263,447.19 | -23,564,668.37 |
| 信用减值损失(新) | 65,121.83 | -10,334,977 | -9,561,131.3 | -5,587,754.58 |
| 其他收益 | 791,053.65 | 4,623,141.28 | 3,275,608.65 | 2,078,660.05 |
| 四、营业利润 | -22,534,596.99 | -207,028,771.62 | -89,830,454.23 | -58,431,058.17 |
| 加:营业外收入 | 8,730.4 | 1,766,055.81 | 1,955,358.43 | 1,916,758.95 |
| 减:营业外支出 | 166,899.58 | 28,685,946.16 | 2,832,970.95 | 1,112,349.75 |
| 五、利润总额 | -22,692,766.17 | -233,948,661.97 | -90,708,066.75 | -57,626,648.97 |
| 减:所得税费用 | 1,555,508.03 | 12,871,136.57 | -15,338,809.84 | -7,907,680.02 |
| 六、净利润 | -24,248,274.2 | -246,819,798.54 | -75,369,256.91 | -49,718,968.95 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -24,248,274.2 | -246,819,798.54 | -75,369,256.91 | -49,718,968.95 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -25,921,384.02 | -245,582,547.3 | -77,150,360.1 | -52,695,852.83 |
| 少数股东损益 | 1,673,109.82 | -1,237,251.24 | 1,781,103.19 | 2,976,883.88 |
| 扣除非经常损益后的净利润 | -25,888,474.77 | -219,785,531.02 | -76,535,346.56 | -53,201,025.17 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.05 | -0.47 | -0.15 | -0.1 |
| (二)稀释每股收益 | -0.05 | -0.47 | -0.15 | -0.1 |
| 八、其他综合收益 | -2,493,891.59 | 6,170,174.69 | 7,332,986.44 | 7,888,484.03 |
| 归属于母公司股东的其他综合收益 | -2,493,891.59 | 6,170,174.69 | 7,332,986.44 | 7,888,484.03 |
| 九、综合收益总额 | -26,742,165.79 | -240,649,623.85 | -68,036,270.47 | -41,830,484.92 |
| 归属于母公司股东的综合收益总额 | -28,415,275.61 | -239,412,372.61 | -69,817,373.66 | -44,807,368.8 |
| 归属于少数股东的综合收益总额 | 1,673,109.82 | -1,237,251.24 | 1,781,103.19 | 2,976,883.88 |
| 公告日期 | 2026-04-30 | 2026-04-30 | 2025-10-31 | 2025-08-21 |
| 审计意见(境内) | | 带强调事项段的无保留意见 | | |